BRANY announces launch of Protocol Builder™
Web-based and iPad tablet application solution for writing investigator-initiated research protocols
(Lake Success, NY) - BRANY has announced the launch of Protocol Builder™, a first-of-its-kind solution to assist researchers in the development of investigator-initiated research protocols. This web-based application, accessible from any desktop and iPad tablet, is designed to provide expert guidance and a step-by-step process to make protocol development faster and less onerous. Resources necessary to navigate the elaborate regulatory infrastructure that surrounds clinical research in the U.S. are at researchers’ fingertips in this thoughtfully designed application.
“Many investigators find the regulatory and compliance hurdles difficult and time-consuming to navigate when writing protocols,” says Kimberly Irvine, Executive Vice President and Chief Operating Officer at BRANY. “Protocol Builder ensures efficiency and accuracy in developing a complete protocol, ready to submit to the IRB. By following the guided steps in Protocol Builder, investigators will save time and be better able to provide an omission-free protocol for review. Our objective with Protocol Builder is to use technology to empower researchers to achieve their research goals with less effort.”
Utilizing a team of leading experts in both consumer design and investigator-initiated clinical research, BRANY developed a step-by-step intuitive approach to building a protocol. BRANY has deconstructed the complex process of writing research protocols and designed a tool that’s innovative, packed with time-saving features, yet easy to use.
While many institutions provide templates and training to investigators writing investigator-initiated protocols, research shows a high degree of dissatisfaction with these tools. Protocol Builder reduces the complexities in investigator-initiated protocol development and is an excellent tool for both experienced and new investigators.
Protocol Builder is available to institutions through corporate licenses, and to individual investigators through single user licenses. For more information or to sign up for a free demo, please visit www.protocolbuilderpro.com, or contact (516) 499-5645.
High-Dose Ocrevus Falls Short of Primary Endpoint in Relapsing Multiple Sclerosis Trial
April 7th 2025In the Phase III MUSETTE study, a higher dose of intravenous Ocrevus (ocrelizumab) did not provide additional benefit in slowing disability progression compared to the currently approved 600mg dose.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
April 3rd 2025Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease, with benefits consistent with injectable semaglutide and other GLP-1 receptor agonists.
